Positive Results From Prior Research

MNTR / Quantum Immunologics Phase I / II Trials are an outgrowth of positive results from prior research studies. 

In a successful Austrian Trial the same OFA protein strand and a less refined immunotherapy treatment was used with Stage IV renal patients with a average survival rate of 10 months.  Instead, 45% of patients survived at least 40 months with either complete remission or stable disease.

In successful American trials marine species with OFA protein strand and Quantum Immunotherapy treatment, 90% of lung tumor colonies were eradicated.  Separately, 67% of mice rejected lethal dose of A20 lymphoma cells.

A German study demonstrated in vitro killing of leukemia cells by T-lymphocytes sensitized to OFA while sparing normal blood cells.